{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016922","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.769960+00:00","generated_at":"2026-06-15T00:53:38.327218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cocrystal Pharma Q1 net loss $5.2M; progresses COVID-19/flu trials; raises $4M","bullets":["Net loss of $5.2M ($0.64/share) vs $4.2M ($0.52) in Q1 2022; R&D expense $3.9M (up from $2.9M).","Cash of $34.0M at March 31, 2023; working capital $33.8M; 8.1M shares outstanding.","Raised $4M via private placement from directors Dr. Phillip Frost and Fred Hassan; Hassan joined board.","Submitted application for Phase 1 trial of COVID-19 oral protease inhibitor CDI-988 in Australia.","Expects to start Phase 2a human challenge study for influenza A candidate CC-42344 in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016922","json":"https://secwatch.observer/filing/0001493152-23-016922.json","markdown":"https://secwatch.observer/filing/0001493152-23-016922.md","text":"https://secwatch.observer/filing/0001493152-23-016922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/0001493152-23-016922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:53:38.327218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"280d7ff8a40ce3a7e66c210048de6f45977bc2d9","claim":"Cocrystal Pharma, Inc. reported financial results for three months ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223016922/0001493152-23-016922-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}